Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID

Bone Marrow Transplantation

Volumn 46, Issue 12, 2011, Pages 1526-1531

  Iguchi, A ^a   Kawamura, N ^a   Kobayashi, R ^b   Takezaki, S I ^a   Ohkura, Y ^a   Inamoto, J ^a   Ohshima, J ^a   Ichikawa, M ^a   Sato, T ^a   Kaneda, M ^a   Cho, Y ^a   Yamada, M ^a   Kobayashi, I ^a   Ariga, T ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO HOKUYU HOSPITAL   (Japan)

Author keywords

cord blood; fludarabine busulfan; reduced intensity SCT; SCT; X SCID

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOSPORIN A; FLUDARABINE; METHYLPREDNISOLONE; MICAFUNGIN;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; BACTERIAL PNEUMONIA; CASE REPORT; CLINICAL EFFECTIVENESS; CORD BLOOD STEM CELL TRANSPLANTATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HLA MATCHING; HUMAN; INFANT; LUNG ASPERGILLOSIS; MALE; PATIENT SAFETY; PRIORITY JOURNAL; RASH; REDUCED INTENSITY CONDITIONING; THERAPY EFFECT; UNRELATED DONORS; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FETAL BLOOD; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; LUNG DISEASES, FUNGAL; MALE; PNEUMONIA, BACTERIAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84856115884     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.338     Document Type: Article

References (35)

1. Fischer A, Le Deist F, Hacein-Bey-Abina S, André-Schmutz I, Basile Gde S, de Villartay JP et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 2005; 203: 98-109.
2. Grunebaum E, Mazzolari E, Porta F, Dallera D, Atkinson A, Reid B et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006; 295: 508-518. (Pubitemid 43200345)
3. Filipovich AH. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant 2008; 42: S49-S52.
4. Buckley RH, Schiff SE, Schiff RI, Market ML, Williams LW, Roberts JL et al. Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340: 508-516. (Pubitemid 29093286)
5. Antoine C, Muller S, Cant A, Cavazzano-Calvo M, Veys P, Vosen J et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-1999. Lancet 2003; 361: 553-560. (Pubitemid 36207472)
6. Haddad E, Landais P, Friedrich N, Gerritsen B, Cavazzana-Calvo M, Morgan G et al. Long-term immune reconstitution and outcome after HLA non-identical T-cell depleted bone marrow transplantation for severe combined immunodeficiency: an European retrospective study of 116 patients. Blood 1998; 91: 3646-3653. (Pubitemid 28225731)
7. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R et al. Outcome of cord blood transplantation from related and unrelated donors. N Eng J Med 1997; 337: 373-382.
8. Barker JN, Davies SM, de For T, Ramsay NKC, Weisdof DJ, Wagner JE. Survival after transplantation of unrelated umbilical cord blood is comparable to that of leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97: 2957-2961.
9. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-2971.
10. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies S, Ramsay NKC et al. Successful transplantation of HLA matched and HLA-mismatched umbilical cord blood from unrelated donor; analysis of engraftment and acute graftversus host disease. Blood 1996; 88: 795-802. (Pubitemid 26333297)
11. Ziegner UHM, Ochs HD, Schanen C, Feig SA, Seyama K, Futatoni T et al. Unrelated umbilical cord stem cell transplantation for X-linked immunodeficiencies. J Pediatr 2001; 138: 570-573. (Pubitemid 32319733)
12. Fagioli F, Biaxin E, Berger M, Nesi F, Saroglia EH, Minero R et al. Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency. Bone Marrow Transplant 2003; 31: 133-136. (Pubitemid 36240506)
13. Knutsen AP, Wall DA. Umbilical cord blood transplantation in severe T cell immunodeficiency disorders: two-year experience. J Clin Immunol 2000; 20: 466-476. (Pubitemid 32099712)
14. Tsuji Y, Imai K, Kajiwara A, Aoki Y, Isoda T, Tomizawa D et al. Hematopoieticstem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years' experience of a single team. Bone Marrow Transplant 2006; 37: 469-477.
15. Bhattacharya A, Slatter MA, Chapman CE, Barge D, Jackson A, Flood TJ et al. Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant 2005; 36: 295-299. (Pubitemid 41195161)
16. Heredia CD, Ortega JJ, Diaz MA, Olive T, Badell I, Gonzalez-Vicent M et al. Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies. Bone Marrow Transplant 2008; 41: 627-633. (Pubitemid 351524001)
17. Cohen A, Uderzo C, van Lint MT, Esperou H, Rovelli A, Bakker B et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by working party for late effects EBMT. Blood 1999; 93: 4109-4115. (Pubitemid 29279252)
18. Leung W, Hudson M, Zhu Y, Rivera GK, Ribeiro RC, Sandlund JT et al. Late effects in survivors of infant leukemia. Leukemia 2000; 14: 1185-1190. (Pubitemid 30445023)
19. Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 2000; 18: 3273-3279.
20. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879-885. (Pubitemid 40070779)
21. Iguchi A, Kobayashi R, Yoshida M, Kobayashi K, Matsuo K, Kitajima I et al. Vascular endothelial growth factor (VEGF) is one of the causative and predictive cytokines of hepatic venoocclusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 2001; 27: 1173-1180. (Pubitemid 32600290)
22. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P et al. Marrow transplantation for severe aplastic anemia: Methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119-125. (Pubitemid 16041720)
23. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637. (Pubitemid 32113394)
24. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. (Pubitemid 28078275)
25. Westerhof GR, Ploemacher RE, Boudewijin A, Blokland I, Dillingh JH, McGown AT et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470-5478.
26. Iguchi A, Kobayashi R, Kaneda M, Kobayashi K. Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation. Pediatr Blood Cancer 2010; 54: 437-443.
27. Rothbarth J, Woutersen RA, Sparidans RW, van der Velde CJ, Mulder GJ. Melphalan antitumor efficacy and hepatotoxicity: The effect of variable infusion duration in the hepatic artery. J Pharmacol Exp Ther 2003; 305: 1098-1103. (Pubitemid 36617988)
28. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J et al. Prospective oral mucositis audit: Oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519-1525.
29. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR et al. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol 2008; 143: 268-273.
30. Shimoni A, Hardan I, Shem-Yov N, Rand A, Herscovici C, Yerushalmi R et al. Comparison between two fludarabinebased reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/ melphalan is associated with higher incidence of acute graftversus-host disease and non-relapse mortality and lower incidence of relapase than fludarabine/busulfan. Leukemia 2007; 21: 2109-2116. (Pubitemid 47423801)
31. Bakker B, Oostdijk W, Bresters D, Walenkamp MJE, Vossen JM, Wit JM. Disturbances of growth and endocrine function after busulfan-based condtioning for haematopoietic stem cell transplantation during infancy and childhood. Bone marrow Transplant 2004; 33: 1049-1056. (Pubitemid 38744793)
32. Barker JN, Scaradavou A, Stevens CE, Rubinstein P. Analysis of 608 umbilical cord blood transplants: HLA is a critical determinant of transplant-related mortality in the postengraftment period even in the absence of acute graft-vs-host disease. Blood 2005; 11(Suppl 1): 102 (abstract no. 92).
33. Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA 2009; 302: 2465-2470.
34. Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp CD, Kurtycz DF et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol 2009; 124: 522-527.
35. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the EasternCooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655. (Pubitemid 13149996)